BRPI0716445A2 - composiÇço farmacÊutica - Google Patents
composiÇço farmacÊuticaInfo
- Publication number
- BRPI0716445A2 BRPI0716445A2 BRPI0716445-9A2A BRPI0716445A BRPI0716445A2 BR PI0716445 A2 BRPI0716445 A2 BR PI0716445A2 BR PI0716445 A BRPI0716445 A BR PI0716445A BR PI0716445 A2 BRPI0716445 A2 BR PI0716445A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84243206P | 2006-09-05 | 2006-09-05 | |
PCT/SE2007/000771 WO2008030161A1 (en) | 2006-09-05 | 2007-09-04 | Pharmaceutical composition comprising candesartan cilexetil |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0716445A2 true BRPI0716445A2 (pt) | 2013-09-17 |
Family
ID=39157499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0716445-9A2A BRPI0716445A2 (pt) | 2006-09-05 | 2007-09-04 | composiÇço farmacÊutica |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080058399A1 (pt) |
EP (1) | EP2063888A4 (pt) |
JP (1) | JP2010502698A (pt) |
KR (1) | KR20090049089A (pt) |
CN (1) | CN101528224A (pt) |
AU (1) | AU2007293727A1 (pt) |
BR (1) | BRPI0716445A2 (pt) |
CA (1) | CA2662040A1 (pt) |
IL (1) | IL197093A0 (pt) |
MX (1) | MX2009002425A (pt) |
NO (1) | NO20090797L (pt) |
WO (1) | WO2008030161A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070249694A1 (en) * | 2005-12-29 | 2007-10-25 | Azaria Caroline A | Metaxalone formulations and methods for the preparation thereof |
KR20090130325A (ko) * | 2007-04-25 | 2009-12-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 약학 부형제 복합체 |
EP2182927A2 (en) * | 2007-08-01 | 2010-05-12 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions of candesartan |
DE102007052070A1 (de) * | 2007-10-30 | 2009-05-07 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Candesartancilexetil |
EP2106789A1 (en) * | 2008-03-31 | 2009-10-07 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising candesartan |
CN101862325B (zh) * | 2009-04-20 | 2013-12-04 | 北京德众万全药物技术开发有限公司 | 一种含有坎地沙坦酯的药物组合物 |
HUP0900384A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate olmesartan medoxomil compositions |
HUP0900376A2 (en) | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate candesartan cilexetil composition |
CZ302789B6 (cs) * | 2009-11-25 | 2011-11-09 | Zentiva, K. S. | Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva |
US8399501B2 (en) * | 2010-03-04 | 2013-03-19 | Theravance, Inc. | Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof |
JP2012051829A (ja) * | 2010-08-31 | 2012-03-15 | Taiyo Yakuhin Kogyo Kk | 安定なアンジオテンシii受容体拮抗作用を示す薬物製剤の設計 |
JP5756651B2 (ja) * | 2011-02-24 | 2015-07-29 | エルメッド エーザイ株式会社 | カンデサルタンシレキセチルを安定化した組成物及びその製造方法 |
JP2013067574A (ja) * | 2011-09-21 | 2013-04-18 | Teva Pharma Japan Inc | 安定化された医薬組成物 |
WO2014010008A1 (ja) * | 2012-07-09 | 2014-01-16 | 東洋カプセル株式会社 | カンデサルタンシレキセチルのカプセル充填用組成物 |
CN102885810B (zh) * | 2012-10-30 | 2015-08-05 | 台州职业技术学院 | 一种坎地沙坦酯双释胶囊及其制备方法 |
JP6379043B2 (ja) | 2013-01-30 | 2018-08-22 | 沢井製薬株式会社 | カンデサルタンシレキセチル含有医薬組成物 |
KR101710441B1 (ko) * | 2015-12-28 | 2017-02-28 | 신풍제약주식회사 | 안정성 및 용출성이 향상된 정제 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100634953B1 (ko) * | 1998-07-20 | 2006-10-17 | 스미스클라인 비참 코포레이션 | 에프로사르탄을 포함하는 생물학적으로 강화된 경구 고형투여 형태의 제제 |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
WO2002030400A1 (fr) * | 2000-10-06 | 2002-04-18 | Takeda Chemical Industries, Ltd. | Preparations solides |
AUPS236902A0 (en) * | 2002-05-16 | 2002-06-13 | Northern Sydney Area Health Service | Composition and method for treating hypertension |
GB0216700D0 (en) * | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
WO2005070398A2 (en) * | 2004-01-23 | 2005-08-04 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents |
WO2005079751A2 (en) * | 2004-01-23 | 2005-09-01 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of candesartan cilexetil |
EP1713795A2 (en) * | 2004-02-11 | 2006-10-25 | Teva Pharmaceutical Industries Ltd. | Candesartan cilexetil polymorphs |
WO2005123721A2 (en) * | 2004-06-18 | 2005-12-29 | Ranbaxy Laboratories Limited | Amorphous and polymorphic forms of candesartan cilexetil |
EP1655298A1 (en) * | 2004-11-03 | 2006-05-10 | LEK Pharmaceuticals d.d. | Novel polymorph forms of candesartan cilexetil |
US20060099230A1 (en) * | 2004-11-10 | 2006-05-11 | Chin-Chih Chiang | Novel formulations of eprosartan with enhanced bioavailability |
US20060111417A1 (en) * | 2004-11-23 | 2006-05-25 | Purandhar Koilkonda | Amorphous telmisartan |
EA200701442A1 (ru) * | 2005-01-06 | 2008-02-28 | Элан Фарма Интернэшнл Лтд. | Композиции наночастиц кандесартана |
KR20080042039A (ko) * | 2005-04-18 | 2008-05-14 | 루비콘 리서치 피브이티. 엘티디. | 생물학적으로 강화된 조성물 |
-
2007
- 2007-09-04 CN CNA2007800328122A patent/CN101528224A/zh active Pending
- 2007-09-04 MX MX2009002425A patent/MX2009002425A/es not_active Application Discontinuation
- 2007-09-04 EP EP07808791A patent/EP2063888A4/en not_active Withdrawn
- 2007-09-04 WO PCT/SE2007/000771 patent/WO2008030161A1/en active Application Filing
- 2007-09-04 AU AU2007293727A patent/AU2007293727A1/en not_active Abandoned
- 2007-09-04 CA CA002662040A patent/CA2662040A1/en not_active Abandoned
- 2007-09-04 JP JP2009527320A patent/JP2010502698A/ja active Pending
- 2007-09-04 BR BRPI0716445-9A2A patent/BRPI0716445A2/pt not_active IP Right Cessation
- 2007-09-04 KR KR1020097006712A patent/KR20090049089A/ko not_active Application Discontinuation
- 2007-09-05 US US11/850,049 patent/US20080058399A1/en not_active Abandoned
-
2009
- 2009-02-17 IL IL197093A patent/IL197093A0/en unknown
- 2009-02-20 NO NO20090797A patent/NO20090797L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20090049089A (ko) | 2009-05-15 |
CN101528224A (zh) | 2009-09-09 |
WO2008030161A1 (en) | 2008-03-13 |
EP2063888A1 (en) | 2009-06-03 |
AU2007293727A1 (en) | 2008-03-13 |
NO20090797L (no) | 2009-03-19 |
JP2010502698A (ja) | 2010-01-28 |
US20080058399A1 (en) | 2008-03-06 |
MX2009002425A (es) | 2009-03-20 |
IL197093A0 (en) | 2009-11-18 |
CA2662040A1 (en) | 2008-03-13 |
EP2063888A4 (en) | 2009-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTC2140867I2 (lt) | Farmacinė kompozicija | |
LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
BRPI0715712A2 (pt) | Composição farmacêutica | |
BRPI0719393A2 (pt) | Composição farmacêutica | |
BRPI0721651A2 (pt) | Composição farmacêutica | |
DK2041139T3 (da) | Farmaceutiske forbindelser | |
RU2398586C3 (ru) | Фармацевтическая композиция | |
BRPI0720234A2 (pt) | Composição farmacêutica | |
BRPI0716445A2 (pt) | composiÇço farmacÊutica | |
BRPI0716325A2 (pt) | Composição antimicrobianas | |
RU2493831C3 (ru) | Фармацевтические композиции | |
FR2899479B1 (fr) | Composition cicatrisante | |
DK2073795T3 (da) | Misbrugssikret lægemiddelformulation | |
BRPI0810928A2 (pt) | "composição farmacêutica" | |
DK1940467T3 (da) | Lægemiddelsammensætning med langvarig frigivelse | |
DK1984009T3 (da) | Farmaceutiske sammensætninger med forbedret stabilitet | |
DK2120884T3 (da) | Farmaceutisk sammensætning | |
DK1986650T3 (da) | Manipulationssikre doserignsformer | |
DK2285413T3 (da) | Farmaceutisk sammensætning | |
BRPI0716458A2 (pt) | Composição de vulcanizado | |
DK2966175T3 (da) | Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat | |
BRPI0817833A2 (pt) | Composição farmacêutica antimalárica | |
BRPI0921313A2 (pt) | composição farmaucêutica | |
BRPI0820198A2 (pt) | composições farmacêuticas | |
BRPI0912171A2 (pt) | composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A, 6A E 7A ANUIDADES. |
|
B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |